Genmab has experienced significant fluctuations in stock prices. Shareholders have endured a 47% loss over the past three years. However, the company also reports promising results such as a 19% revenue growth and a 62% surge in operating profit in Q1 2025. Several changes in executive committee and updates in articles of association were made to facilitate strategic growth. The company also completed a share
buy-back program, repurchasing 2.2 million shares. Meanwhile, the
Underperformer views are backed by the termination of collaboration with J&J on
HexaBody-CD38, despite a 55% response rate. Analysts' views on the company oscillate, with some considering it the most undervalued and profitable healthcare stock, while others have lowered their price targets. The company also faces legal issues, including a trade secret claim by AbbVie. Despite pressures, Genmab announces more buy-back transactions and awarded stock units and warrants to employees.
Genmab Stocks News Analytics from Wed, 04 Sep 2024 07:00:00 GMT to Fri, 04 Jul 2025 09:50:40 GMT -
Rating 2
- Innovation 3
- Information 6
- Rumor -2
